8-K filing — Lipocine Inc. (LPCN)
Filed: 2026-10-20 AccNo: 0001493152-26-047693 Size: 17 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Lipocine Q2 EPS $(0.32) Beats $(0.43) Estimate, Sales $190.099K Beat $156.500K Estimate
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.43) by 25.58 percent. This is a 21.95 percent increase over losses of $(0.41) per share from the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nasdaq Falls Over 100 Points; US Crude Inventories Decline
U.S. stocks fell Wednesday, led by industrials. Crude inventories dropped unexpectedly, while Penguin Solutions and Lipocine surged; Caribou Biosciences
Canadian Approval Of Lipocine Drug Marks Progress for Oral Testosterone Options In Canada
Canada approves Lipocine’s TLANDO for adult males with testosterone deficiency. Partner Verity Pharma plans a launch by the end of 2026.
Dow Tumbles 350 Points; Constellation Brands Earnings Top Views
U.S. stocks fell Wednesday; Dow dropped 350 points. Energy rose, materials slid. Constellation beat estimates; oil gained while gold and silver fell.